FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303487> ?p ?o ?g. }

• W4367303487 abstract "<h3>Objective:</h3> To evaluate patient treatment effects beyond TOPAZ trial endpoint measures to provide a deeper understanding of the potential benefit of apitegromab. <h3>Background:</h3> SMA is caused by deletion or mutation in SMN1 gene and is characterized by motor neuron deterioration that contributes to progressive muscle weakness and loss of motor function. Current SMN treatments have shown improvements in motor function; however, limitations remain that contribute to unmet needs. In a Phase 2 trial (TOPAZ, NCT03921528), we have reported safety and efficacy of apitegromab, a selective myostatin inhibitor, in patients with Types 2/3 SMA. HFMSE and RHS scales were used to evaluate efficacy. <h3>Design/Methods:</h3> This qualitative, cross-sectional study aimed to gain insights into the impact of SMA and potential treatment benefits based on patient’s/caregiver’s perceptions of SMA and experience with treatment during the TOPAZ trial through 24 months. A subset of 15 patients were invited to participate in a 2 hour semi-structured interview about their experience with SMA and perceptions of meaningful treatment benefit during the trial. Treatment effects observed during the trial were compared to pre-treatment signs and symptoms. <h3>Results:</h3> Twelve patients/caregivers were interviewed. Participants reported substantial burden in signs and symptoms associated with SMA including muscle weakness, fatigue, problems with balance, respiratory problems, and bowel difficulties. They also reported impacts of SMA on physical function, dependency, daily activities, and social activities. Improvements in signs, symptoms and impacts of SMA after treatment will be reported. <h3>Conclusions:</h3> The symptoms and impacts of living with SMA as reported by 12 patients/caregivers provided insight related to meaningful treatment benefits experienced while receiving apitegromab during the TOPAZ trial, particularly around activities of daily living, fatigue, muscle weakness, physical functioning, independence, and balance. These data provide supplemental insights beyond what may be captured in a standardized questionnaire and give insight to the holistic improvement in the patient’s quality of life. <b>Disclosure:</b> Dr. Pokrzywinski has received personal compensation for serving as an employee of Evidera. Katelyn Cutts has nothing to disclose. The institution of Dr. Shah has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Scholar Rock. Dr. Kertesz has received personal compensation for serving as an employee of Scholar Rock Inc.. Dr. Lesh has received personal compensation for serving as an employee of Scholar Rock, Inc.. Mrs. E Sadanowicz has nothing to disclose. Guochen Song has received personal compensation for serving as an employee of Scoloar Rock. An immediate family member of Guochen Song has received personal compensation for serving as an employee of United Health Group. Guochen Song has stock in Scholarrock. Guochen Song has stock in BIogen. Ms. ONeil has nothing to disclose. Doreen Barrett has received personal compensation for serving as an employee of Scholar Rock. Mrs. Barnobi has received personal compensation for serving as an employee of Scholar Rock. Scott Baver has received personal compensation for serving as an employee of Scholar Rock." @default.
• W4367303487 created "2023-04-29" @default.
• W4367303487 creator A5000602247 @default.
• W4367303487 creator A5017801560 @default.
• W4367303487 creator A5026872313 @default.
• W4367303487 creator A5037213636 @default.
• W4367303487 creator A5054612368 @default.
• W4367303487 creator A5065272300 @default.
• W4367303487 creator A5068121215 @default.
• W4367303487 creator A5077732711 @default.
• W4367303487 creator A5082080191 @default.
• W4367303487 creator A5085701049 @default.
• W4367303487 creator A5088556035 @default.
• W4367303487 date "2023-04-25" @default.
• W4367303487 modified "2023-10-15" @default.
• W4367303487 title "Treatment Effects Among Patients with Type 2 and Type 3 SMA Directly Reported by Patients and Caregivers from the TOPAZ Clinical Trial (P2-8.010)" @default.
• W4367303487 doi "https://doi.org/10.1212/wnl.0000000000203207" @default.
• W4367303487 hasPublicationYear "2023" @default.
• W4367303487 type Work @default.
• W4367303487 citedByCount "0" @default.
• W4367303487 crossrefType "proceedings-article" @default.
• W4367303487 hasAuthorship W4367303487A5000602247 @default.
• W4367303487 hasAuthorship W4367303487A5017801560 @default.
• W4367303487 hasAuthorship W4367303487A5026872313 @default.
• W4367303487 hasAuthorship W4367303487A5037213636 @default.
• W4367303487 hasAuthorship W4367303487A5054612368 @default.
• W4367303487 hasAuthorship W4367303487A5065272300 @default.
• W4367303487 hasAuthorship W4367303487A5068121215 @default.
• W4367303487 hasAuthorship W4367303487A5077732711 @default.
• W4367303487 hasAuthorship W4367303487A5082080191 @default.
• W4367303487 hasAuthorship W4367303487A5085701049 @default.
• W4367303487 hasAuthorship W4367303487A5088556035 @default.
• W4367303487 hasConcept C11413529 @default.
• W4367303487 hasConcept C126322002 @default.
• W4367303487 hasConcept C141071460 @default.
• W4367303487 hasConcept C161921814 @default.
• W4367303487 hasConcept C168563851 @default.
• W4367303487 hasConcept C1862650 @default.
• W4367303487 hasConcept C2780247198 @default.
• W4367303487 hasConcept C41008148 @default.
• W4367303487 hasConcept C535046627 @default.
• W4367303487 hasConcept C71924100 @default.
• W4367303487 hasConcept C99508421 @default.
• W4367303487 hasConceptScore W4367303487C11413529 @default.
• W4367303487 hasConceptScore W4367303487C126322002 @default.
• W4367303487 hasConceptScore W4367303487C141071460 @default.
• W4367303487 hasConceptScore W4367303487C161921814 @default.
• W4367303487 hasConceptScore W4367303487C168563851 @default.
• W4367303487 hasConceptScore W4367303487C1862650 @default.
• W4367303487 hasConceptScore W4367303487C2780247198 @default.
• W4367303487 hasConceptScore W4367303487C41008148 @default.
• W4367303487 hasConceptScore W4367303487C535046627 @default.
• W4367303487 hasConceptScore W4367303487C71924100 @default.
• W4367303487 hasConceptScore W4367303487C99508421 @default.
• W4367303487 hasLocation W43673034871 @default.
• W4367303487 hasOpenAccess W4367303487 @default.
• W4367303487 hasPrimaryLocation W43673034871 @default.
• W4367303487 hasRelatedWork W1431994528 @default.
• W4367303487 hasRelatedWork W2013301809 @default.
• W4367303487 hasRelatedWork W2121965889 @default.
• W4367303487 hasRelatedWork W2418653140 @default.
• W4367303487 hasRelatedWork W25111752 @default.
• W4367303487 hasRelatedWork W3159250744 @default.
• W4367303487 hasRelatedWork W4256514411 @default.
• W4367303487 hasRelatedWork W4292236216 @default.
• W4367303487 hasRelatedWork W4292280753 @default.
• W4367303487 hasRelatedWork W2083697902 @default.
• W4367303487 isParatext "false" @default.
• W4367303487 isRetracted "false" @default.
• W4367303487 workType "article" @default.